BRAF inhibitors are effective in treatment but were limited by acquired resistance in cancer cells; when BRAF inhibitor treatment was paired with targeted MEK inhibition, this acquired resistance was effectively delayed [64]. This evidence concerns the gene MAP2K7 and cancer.